We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Scientists Validate Method to Measure Protein Interactions

By Biotechdaily staff writers
Posted on 04 May 2004
Researchers working with the p73 homologue of the tumor-suppressor gene p73 have described the mechanism by which the Wwox tumor suppressor protein interacts with p73, an interaction that increases apoptosis and decreases the likelihood of tumor development.

The p73 gene shares many structural and functional features of p53, including a 63% homology with a remarkable conservation of critical residues that are known to be important for the binding of p53 to target genes or proper folding of p53. More...
The C-terminal domain of p53 and p73 are quite distinct, however. The p73 gene has been mapped to human chromosome 1p36, a region that is frequently deleted in a variety of human cancers including neuroblastoma, colon cancer, and breast cancer.

Scientists at Thomas Jefferson University (Philadelphia, PA, USA) and researchers at Cytogen Corp. (Princeton, NJ, USA) reported in the March 30, 2004, issue of the Proceedings of the [U.S.] National Academy of Sciences that Wwox physically interacted via its first WW domain with the p53 homologue, p73. The tyrosine kinase, Src, phosphorylated Wwox at tyrosine 33 in the first WW domain and enhanced its binding to p73. Wwox expression triggered redistribution of nuclear p73 to the cytoplasm and, hence, suppressed its transcriptional activity. In addition, cytoplasmic p73 contributed to the activity of Wwox leading to apoptosis. These findings were obtained using Cytogen's in vitro signal transduction pathway discovery platform.

"In the present study, we have demonstrated the physical interaction between the recently discovered Wwox and the p53 homologue, p73,” explained senior author Dr.Carlo Croce, professor of microbiology and immunology at Thomas Jefferson University. "Since the Wwox protein contains two WW domains that are generally known to mediate protein-protein interaction, Cytogen's robust WW domain interaction data allowed us to efficiently reveal a functional cross-talk between p73 and the Wwox tumor suppressor protein. The study results help establish that the company's high-throughput method to measure protein interactions compares favorably with other more complex techniques and further validates this method of elucidating and identifying protein interactions.”





Related Links:
Thomas Jefferson University
Cytogen Corp.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.